Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine in children and adolescents 6 months through 17 years of age in India

References

• World Health Organization (WHO). Influenza (seasonal)-ask the experts: Q&A. WHO; 2018 Nov 6 Archived from the original on 2019 Oct 25 [accessed 2020 Jun 16]. https://www.who.int/news-room/fact-sheets/detail/influenza-seasonal.
   Google Scholar
• Content source: Centers for Disease Control and Prevention, National Center for ×Immunization and Respiratory Diseases. Types of influenza viruses. U.S. Department of Health & Human Services; 2019 Nov 18 [accessed 2020 Jun 16]. https://www.cdc.gov/flu/about/viruses/types.htm.
   Google Scholar
• Iuliano AD, Roguski KM, Chang HH, Muscatello DJ, Palekar R, Tempia S, Cohen C, Gran JM, Schanzer D, Cowling BJ, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet. 2018;391(10127):1–9. PMID: 29248255. doi:10.1016/S0140-6736(17)33293-2.
   PubMed Web of Science ®Google Scholar
• Immunization Action Coalition (IAC). Influenza: questions and answers information about the disease and vaccines. Saint Paul, Minnesota: IAC; 2020 [accessed 2020 Feb 6]; https://www.immunize.org/catg.d/p4208.pdf.
   Google Scholar
• World Health Organization (WHO). Biologicals: influenza. WHO; 2019 Jun 19 [accessed 2020 Jun 12]. http://www.who.int/biologicals/vaccines/influenza/en/.
   Google Scholar
• Viboud C, Boelle PY, Cauchemez S, Lavenu A, Valleron AJ, Flahault A, Carrat F. Risk factors of influenza transmission in households. Br J Gen Pract. 2004;54(506):684–689. PMID: 15353055
   PubMed Web of Science ®Google Scholar
• Glass LM, Glass RJ. Social contact networks for the spread of pandemic influenza in children and teenagers. BMC Publ Health. 2008 PMID: 18275603;8(1):61. doi:10.1186/1471-2458-8-61.
   PubMedGoogle Scholar
• Schanzer D, Vachon J, Pelletier L. Age-specific differences in influenza a epidemic curves: do children drive the spread of influenza epidemics? Am J Epidemiol. 2011;174(1):109–117. PMID: 15353055. doi:10.1093/aje/kwr037.
   PubMed Web of Science ®Google Scholar
• von Kries R, Weiss S, Falkenhorst G, Wirth S, Kaiser P, Huppertz HI, Tenenbaum T, Schroten H, Streng A, Liese J, et al. Post-Pandemic seroprevalence of pandemic influenza a (H1N1) 2009 infection (swine flu) among children <18 years in Germany. PLoS One. 2011;6(9):e23955. PMID: 21915270. doi:10.1371/journal.pone.0023955.
   PubMed Web of Science ®Google Scholar
• Purakayastha DR, Vishnubhatla S, Rai SK, Broor S, Krishnan A. Estimation of burden of influenza among under-five children in India: a meta-analysis. J Trop Pediatr. 2018;64(5):441–453. PMID: 29112737. doi:10.1093/tropej/fmx087.
   PubMed Web of Science ®Google Scholar
• Narayan VV, Iuliano AD, Roguski K, Bhardwaj R, Chadha M, Saha S, Haldar P, Kumar R, Sreenivas V, Kant S, et al. Burden of influenza-associated respiratory and circulatory mortality in India, 2010-2013. J Glob Health. 2020;10(1):010402. PMID: 32373326. doi:10.7189/jogh.10.010402.
   PubMed Web of Science ®Google Scholar
• Flannery B, Reynolds SB, Blanton L, Santibanez TA, O’Halloran A, Lu PJ, Chen J, Foppa IM, Gargiullo P, Bresee J, et al. Influenza vaccine effectiveness against pediatric deaths: 2010–2014. Pediatrics. 2017;139(5):e20164244. PMID: 28557757. doi:10.1542/peds.2016-4244.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Study of flu-related deaths in children shows healthy children at risk. U.S.CDC. 2018 Feb 12 [accessed 2020 Jun 12]. https://www.cdc.gov/flu/spotlights/2017-2018/flu-death-children.htm.
   Google Scholar
• Thompson MG, Clippard J, Petrie JG, Jackson ML, McLean HQ, Gaglani M, Reis EC, Flannery B, Monto AS, Jackson L, et al. Influenza vaccine effectiveness for fully and partially vaccinated children 6 months to 8 years old during 2011–2012 and 2012–2013. Pediatr Infect Dis J. 2016;35(3):299–308. PMID: 26658375. doi:10.1097/INF.0000000000001006.
   PubMed Web of Science ®Google Scholar
• SAGE Working Group. Background paper on influenza vaccines and immunization. 2012. https://www.who.int/immunization/sage/meetings/2012/april/1_Background_Paper_Mar26_v13_cleaned.pdf.
   Google Scholar
• Committee on Infectious Diseases. Recommendations for prevention and control of influenza in children, 2019–2020. Pediatrics 2019;144:e20192478. PMID: 31477606. doi:10.1542/peds.2019-2478.
   PubMed Web of Science ®Google Scholar
• Domachowske JB, Pankow-Culot H, Bautista M, Feng Y, Claeys C, Peeters M, Bl I, Jain V. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years. J Infect Dis. 2013;207:1878–1887. PMID: 23470848. doi:10.1093/infdis/jit091.
   PubMed Web of Science ®Google Scholar
• Greenberg DP, Robertson CA, Landolfi VA, Bhaumik A, Senders SD, Decker MD. Safety and immunogenicity of an inactivated quadrivalent influenza vaccine in children 6 months through 8 years of age. Pediatr Infect Dis J. 2014;33:630–636. PMID: 24445833. doi:10.1097/INF.0000000000000254.
   PubMed Web of Science ®Google Scholar
• Rodriguez Weber MA, Claeys C, Aranza Doniz C, Feng Y, Innis BL, Jain VK, Peeters M. Immunogenicity and safety of inactivated quadrivalent and trivalent influenza vaccines in children 18–47 months of age. Pediatr Infect Dis J. 2014;33(12):1262–1269. PMID: 25386965. doi:10.1097/INF.0000000000000463.
   PubMed Web of Science ®Google Scholar
• Langley JM, Martinez AC, Chatterjee A, Halperin SA, McNeil S, Reisinger KC, Aggarwal N, Huang LM, Peng CT, Garcia-Sicilia J, et al. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: a phase III randomized controlled trial in children. J Infect Dis. 2013;208(4):544–553. PMID: 23847058. doi:10.1093/infdis/jit263.
   PubMed Web of Science ®Google Scholar
• You JH, Ming WK, Chan PK. Cost-Effectiveness of quadrivalent influenza vaccine in Hong Kong – a decision analysis. Hum Vaccin Immunother. 2015;11(3):564–571. PMID: 25714506. doi:10.1080/21645515.2015.1011016.
   PubMed Web of Science ®Google Scholar
• Jain VK, Rivera L, Zaman K, Espos JR, Sirivichayakul C, Quiambao BP, Rivera-Medina DM, Kerdpanich P, Ceyhan M, Dinleyici EC, et al. Vaccine for prevention of mild and moderate-to-severe influenza in children. N Engl J Med. 2013;369(26):2481–2491. PMID: 24328444. doi:10.1056/NEJMoa1215817.
   PubMed Web of Science ®Google Scholar
• Basu I, Agarwal M, Shah V, Shukla V, Naik S, Supe PD, Srivastava MK, Giriraja KV, Pinjar P, Mishra PK, et al. Immunogenicity and safety of two quadrivalent influenza vaccines in healthy adult and elderly participants in India - a phase III, active-controlled, randomized clinical study. Hum Vaccin Immunother. 2021;1–10. PMID: 33957854. doi:10.1080/21645515.2021.1885278.
   PubMed Web of Science ®Google Scholar
• Wijnans L, Voordouw B. A review of the changes to the licensing of influenza vaccines in Europe. Influenza Other Respir Viruses. 2016;10:2–8. doi:10.1111/irv.12351.
   Google Scholar
• Trombetta CM, Perini D, Mather S, Temperton N, Montomoli E. Overview of serological techniques for influenza vaccine evaluation: past, present and future. Vaccines (Basel). 2014;2(4):707–734. PMID: 26344888. doi:10.3390/vaccines2040707.
   PubMedGoogle Scholar
• World Health Organization. FluNet - Global Influenza Surveillance and Response System (GISRS). [accessed 2020 Jun 24]. http://www.who.int/influenza/gisrs_laboratory/flunet/en/.
   Google Scholar
• de Jong JC, Palache AM, Beyer WE, Rimmelzwaan GF, Boon AC, Osterhaus AD. Haemagglutination-Inhibiting antibody to influenza virus. Dev Biol (Basel). 2003;115:63–73. PMID: 15088777.
   PubMedGoogle Scholar
• Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond). 1972;70(4):767–777. PMID: 4509641. doi:10.1017/s0022172400022610.
   PubMedGoogle Scholar
• Vesikari T, Nauta J, Lapini G, Montomoli E, van de Witte S. Immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in children and adolescents: a phase III randomized study. Int J Infect Dis. 2020;92:29–37. PMID: 31838217. doi:10.1016/j.ijid.2019.12.010.
   PubMed Web of Science ®Google Scholar
• Hervé C, Laupèze B, Del Giudice G, Didierlaurent AM, Da Silva FT. The how’s and what’s of vaccine reactogenicity. NPJ Vaccines. 2019;4(1):39. PMID: 31583123. doi:10.1038/s41541-019-0132-6.
   PubMed Web of Science ®Google Scholar